Page 123 - Drug Class Review
P. 123
Drug Effectiveness Review Project
Drugs Authors: Jones et al. 28 Country: Multinational (UK, Finland, Germany, Norway) Eisai Inc., Pfizer Inc. To directly compare the effectiveness and tolerability of DON and GAL in the treatment of AD and investigate effects of both treatments on cognition and activities of daily living Study design: RCT (open-label) Setting: Multi-center (14 centers ) donepezil galantamine 5-10 mg once daily 4-12 mg twice daily 12 weeks 12 weeks 64 56 At least 50 years of age diagnosed with probable or possible mild to moderate AD consistent with NINCDS/ADRDA and DSM-IV criteria; MMSE
Alzheimer Year: 2004 Sample size: 120 NR
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
